Back to search

Article

Effect of Alirocumab on Coronary Plaque in Patients With Coronary Artery Disease Assessed by Optical Coherence Tomography

2021-07-09

Abstract excerpt

<h4>Background: </h4> Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been demonstrated with significant greater reduction of LDL cholesterol levels and cardiovascular events, compared with standard statin therapy. However, the evidence on the impact of PCSK9 inhibitors on coronary plaque composition and morphology are limited. <h4>Methods: </h4> In this prospective, open-label, randomized st...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
28f7d926-4bef-5573-a0f2-bd0d1617571b
DOI
10.21203/rs.3.rs-685343/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effect of Alirocumab on Coronary Plaque in Patients With Coronary Artery Disease Assessed by Optical Coherence TomographyDOI 10.21203/rs.3.rs-685343/v1
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.Semantic proximity
Efficacy and Safety of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With Proprotein Convertase Subtilisin/Kexin Type 9 Gain-of-Function or Apolipoprotein B Loss-of-Function Mutations.Semantic proximity
Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study.Semantic proximity
The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab.Semantic proximity
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I.Semantic proximity
Accelerating Drug TranslationSemantic proximity
Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels.Semantic proximity
Achieved LDL-C levels <55 mg/dL and cardiac events in patients and lesions harbouring lipid-rich plaque phenotypes.Semantic proximity
The impact of Mediterranean diet on coronary plaque vulnerability, microvascular function, inflammation, and microbiome after an acute coronary syndrome: study protocol for the MEDIMACS randomized, controlled, mechanistic clinical trial.Semantic proximity
Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events: a systematic review and meta-regression analysis.Semantic proximity
Assessing the Impact of Long-term High-Dose Statin Treatment on Pericoronary Inflammation and Plaque Distribution - a Comprehensive Coronary CTA Follow-up StudySemantic proximity
Sodium-glucose Cotransporter-2 Inhibitors Stabilize Coronary Plaques in Acute Coronary Syndrome with Diabetes MellitusSemantic proximity
Select a neighboring publication to make it the new centre.